ROIVANT SCIENCES LTD. Intangible Assets, Net (Excluding Goodwill)
ROIVANT SCIENCES LTD. (ROIV) had Intangible Assets, Net (Excluding Goodwill) of $136.01 million as of 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2024-08-09
- 2024-06-30: Intangible Assets, Net (Excluding Goodwill) $136.01M.
- 2024-03-31: Intangible Assets, Net (Excluding Goodwill) $137.84M.
- 2023-12-31: Intangible Assets, Net (Excluding Goodwill) $150.41M.
- 2023-09-30: Intangible Assets, Net (Excluding Goodwill) $140.62M.
| Period end | Intangible Assets, Net (Excluding Goodwill) |
|---|---|
| 2024-06-30 | $136.01M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $137.84M 10-Q · filed 2024-08-09 |
| 2023-12-31 | $150.41M 10-Q · filed 2024-02-13 |
| 2023-09-30 | $140.62M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $145.04M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $144.88M 10-K · filed 2024-05-30 |
| 2022-12-31 | $146.10M 10-Q · filed 2023-02-13 |
| 2022-09-30 | $140.30M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $145.43M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $0.00 10-K · filed 2023-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |